SC 13G/A: KAZIA THERAPEUTICS LTD
Ticker: KZIA · Form: SC 13G/A · Filed: Aug 12, 2024 · CIK: 1075880
| Field | Detail |
|---|---|
| Company | Kazia Therapeutics LTD (KZIA) |
| Form Type | SC 13G/A |
| Filed Date | Aug 12, 2024 |
| Risk Level | low |
| Pages | 8 |
| Reading Time | 10 min |
| Key Dollar Amounts | $15,000,000, $6,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by KAZIA THERAPEUTICS LTD.
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G/A filing submitted by Kazia Therapeutics LTD (ticker: KZIA) to the SEC on Aug 12, 2024.
What is the risk level of this SC 13G/A filing?
This filing has been assessed as low risk.
What are the key financial figures in this filing?
Key dollar amounts include: $15,000,000 (ompany may sell to Alumni Capital up to $15,000,000 (the “Investment Amount”),); $6,000,000 (rcise price is variable and is equal to $6,000,000 divided by the number of outstanding Or).
How long is this filing?
Kazia Therapeutics LTD's SC 13G/A filing is 8 pages with approximately 2,480 words. Estimated reading time is 10 minutes.
Where can I view the full SC 13G/A filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 2,480 words · 10 min read · ~8 pages · Grade level 11.6 · Accepted 2024-08-12 19:28:02
Key Financial Figures
- $15,000,000 — ompany may sell to Alumni Capital up to $15,000,000 (the “Investment Amount”),
- $6,000,000 — rcise price is variable and is equal to $6,000,000 divided by the number of outstanding Or
Filing Documents
- ea0211201-13gaalumni_kazia.htm (SC 13G/A) — 70KB
- 0001213900-24-067831.txt ( ) — 71KB
(a)
Item 1(a) Name of Issuer : Kazia Therapeutics Limited
(b)
Item 1(b) Address of Issuer’s Principal Executive Offices : Three International Towers Level 24. 300 Barangaroo Avenue Sydney, NSW, 2000, Australia
(a)
Item 2(a) Name of Person Filing : Alumni Capital LP Alumni Capital GP LLC Ashkan Mapar, Manager of Alumni Capital GP LLC
(b)
Item 2(b) Address of Principal Business Office or, if none, Residence : The address for the principal business office of each of Alumni Capital LP, Alumni Capital GP LLC, and Ashkan Mapar is: 80 S.W. 8 TH Street Suite 2000 Miami, FL 33131
(c)
Item 2(c) Citizenship : Alumni Capital LP, Delaware limited partnership Alumni Capital GP LLC, Delaware limited liability company Ashkan Mapar, USA
(d)
Item 2(d) Title of Class of Securities : American Depository Shares, no par value
(e)
Item 2(e) CUSIP No. : 48669G105 Item 3 If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a : The statement is not filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c). Item 4 (a) Amount beneficially owned: 1,587,925 (1) (b) Percent of class: 3.96 % (2) (c) Number of shares as to which the person has: (i) Sole power to vote or direct the vote: 1,587,925 American Depository Shares (1) 5 (ii) Shared power to vote or direct the vote; 0 shares (iii) Sole power to dispose of or direct the disposition of : 1,587,925 American Depository Shares (1) (iv) Shared power to dispose or direct the disposition of : 0 (1) All of the shares are owned beneficially by Alumni Capital LP. Ashkan Mapar may be deemed to possess voting and dispositive power in his capacity as manager of Alumni Capital GP, LLC; however, Ashkan Mapar disclaims beneficial ownership of these shares. (a) Such ADSs represent beneficial ownership of 3.96% of the shares outstanding, based on 38,527,956 ADSs issued and outstanding as of August 9, 2024 plus 1,587,925 ADSs issuable upon exercise of the Warrant. (b) Alumni Capital GP LLC is the general partner of Alumni Capital LP and in that capacity has voting and dispositive power over the shares owned by Alumni Capital LP. Alumni Capital GP LLC does not itself own any securities of the issuer. Alumni Capital GP, LLC is thus the beneficial owner of 1,587,925 ADSs. Such ADSs represent beneficial ownership of 3.96% of the shares outstanding, based on 38,527,956 ADSs issued and outstanding as of August 9, 2024 plus 1,587,925 ADSs issuable upon exercise of the Warrant. (2) Based on 38,527,956 ADSs issued and outstanding as of August 9, 2024 plus 1,587,925 ADSs issuable upon exercise of the Warrant. Item 5. Not applicable. Item 6 N